linjc16/ctgov huggingface dataset:
LUNG INFECTION IN ICU (LUNG-I3)

Study Overview
=================
Brief Summary
-----------------
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

Official Title
-----------------
LUNG INFECTION IN ICU

Conditions
-----------------
VAP - Ventilator Associated Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the following criteria Age 18 years or greater Severe ICU patients hospitalized for one of the above diseases: Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20) Severe trauma (level I and II), Injury Severity Score ≥ 25 OR Burn with TBSA over 20% NAD > 0.1 µg/kg/min At least 2 SOFA criteria ≥ 2 points Exclusion Criteria: Aspiration pneumonia Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.) COPD Smoke inhalation in burn patients Participation in an intervention study Pregnant or breastfeeding women Immunocompromised patients, defined as patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease hematologic malignancies solid organ transplantation HIV infection with or without AIDS treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day) treatment with other immunosuppressive drugs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| immune cells patterns in VAP | The primary endpoint will be to describe and compare the distribution of immune cells within the lung and the blood before VAP diagnosis (VAP prediction) and at the time of VAP diagnosis. | before and at time of VAP diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VAP - Ventilator Associated Pneumonia, Sepsis, Lung Infection, Broncho-alveolar Lavage, ICU
Influence of Students Behaviors on Performance and Quality of Life on the OSCE

Study Overview
=================
Brief Summary
-----------------
The students behave differentially before an exam. This study aims at determining the influence of all these behaviors on the perceived quality of life of students and their performance during their OSCE.

Detailed Description
-----------------
The students behave differentially before an exam. They can be discriminate, on their sleeping, coping, or physical activity behavior. They also show difference in the number of hours they study by weeks or if they use the services offer by their university. This study aims at determining the influence of all these behaviors on the perceived quality of life of students and their performance during their OSCE (a major exam).

Official Title
-----------------
Influence of Students Behaviors on Thier Performance and Quality of Life on the OSCE

Conditions
-----------------
Objective Structured Clinical Examination, Performance Anxiety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all volontary medical students of the third cycle that came for their exam during the sessions of December and May 2023 from the University of Lyon (Medecine ESt) Exclusion Criteria: no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PERFORMANCE | Score at the OSCE exam from 0 to 40 points | obtained 7 days after the OSCE | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SF-12 | Overall quality of life | obtained one hour after the OSCE | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stress, physical activity, sedentarity, sleep, quality of life, coping
A Comparison of Metacarpophalangeal Joint Blocking Splint With Relative Motion Extension Splint for Trigger Finger

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to evaluate the effectiveness of two splint designs in conservative management of trigger finger.

Detailed Description
-----------------
This study aims to analyse and compare the effectiveness of metacarpophalangeal joint blocking splint versus relative motion extension splint for trigger finger. This will help us find out which one of the two splint designs is more effective in the management of trigger finger, thus improving treatment outcomes for patients with trigger finger.

Official Title
-----------------
A Comparison of Metacarpophalangeal Joint Blocking Splint With Relative Motion Extension Splint for Trigger Finger

Conditions
-----------------
Trigger Finger

Intervention / Treatment
-----------------
* Other: Splint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Trigger finger patient Exclusion Criteria: Diabetes, non-English speaking
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Splint M<br>Metacarpophalangeal joint blocking splint | Other: Splint<br>* Comparison of splints for trigger finger<br>|
| Experimental: Splint R<br>Relative motion extension splint | Other: Splint<br>* Comparison of splints for trigger finger<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Green's classification for trigger finger | Green's classification is an objective outcome measure. The therapist grades the triggering by observing the finger when the patient makes a full fist. Grade I: Pain/history of catching Grade II: Demonstrable catching but can actively extend digit Grade III: Demonstrable locking, requiring passive extension Grade IV: Fixed flexion contracture Lowest score is I; highest score is IV | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QuickDASH (Disability of Arm, Shoulder and Hand) | The QuickDASH is a patient rated questionnaire that rates patient's ability to perform certain tasks as well as severity of symptoms. The best score is 0 (no difficulty) and the lowest score is 100 (severe difficulty). | 12 weeks |
Correlation of Pelvic Asymmetry and Joint Movement During Gait in Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
the study's particular goals were to determine whether excessive hip, knee, and ankle displacement at first contact during locomotion correlates with pelvic rotation.

Official Title
-----------------
Correlation of Pelvic Asymmetry and Joint Movement During Gait in Children With Cerebral Palsy

Conditions
-----------------
Correlation of Pelvic Asymmetry and Joint Movement During Gait in Children With Cerebral Palsy

Intervention / Treatment
-----------------
* Device: three dimensional formetric system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the lower extremities' degree of spasticity ranged from grade 1 to grade +1 on the Gross Motor Function Classification System (GMFCS) [7] classified motor function levels as being between levels I and II. Children have the cognitive ability to understand and follow instructions. Exclusion Criteria: having an extensive intellectual disability, orthopedic issues, upper or lower limb surgery, visual or hearing issues, usage of behavior-altering medicines, or a major neurological illness (epilepsy)

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pelvic asymmetry and joints movement measures | A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner. the Unit of measures detected by degrees | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral palsy, pelvic obliquity, joint movement
Detection of Eating Disorders in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Eating disorders (ED) are insufficiently detected and belatedly or not treated during pregnancy. There are many screening questionnaires for eating disorders in the literature, but we note the absence of a specific and validated tool for their screening during pregnancy, which would make it possible to differentiate maternal dietary concerns related to pregnancy from symptoms linked to a proven eating disorder. The main objective of the study is to evaluate which items of the Sick Control One stone Fat Food (SCOFF-F) and Eating disorders examination questionnaire (EDE-Q) questionnaires could be specific to an ED during pregnancy and not related to the simple state of pregnancy, by comparing the answers of pregnant women, for whom the diagnosis of ED has been made, to those of pregnant women without an ED.

Official Title
-----------------
Detection of Eating Disorders in Pregnant Women

Conditions
-----------------
Eating Disorders, Pregnancy Related

Intervention / Treatment
-----------------
* Diagnostic Test: Administration of the SCOFF-F and EDE-Q questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult pregnant woman Woman with current diagnosed Eating Disorders or without Eating Disorders Having a good command of the French language Having given their consent for their participation in the research Exclusion Criteria: Underage pregnant woman Woman who does not have a good command of the French language. Woman with past Eating Disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Group of pregnant women with eating disorder<br> | Diagnostic Test: Administration of the SCOFF-F and EDE-Q questionnaires<br>* The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions<br>|
| Other: Group of pregnant women with no eating disorder<br> | Diagnostic Test: Administration of the SCOFF-F and EDE-Q questionnaires<br>* The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specific Eating Disorders items in pregnant women | A discriminant factor analysis will be used to study whether there are elements that can distinguish women with an Eating Disorders from those who do not have one during pregnancy. | 36 months |
Role Of Metabolic Adaptation In Weight Regain

Study Overview
=================
Brief Summary
-----------------
In a previous study (NCT04081337), 55 participants with obesity participated on a 18-week lifestyle intervention to reduce their body weight, targeting 10% body weight loss. The participants received tirzepatide (15mg after titration) or placebo during the weight loss intervention. Before and after the lifestyle intervention, energy expenditure (48-h room indirect calorimetry) and body weight and composition (dual-X-ray absorptiometry) were measured, thus enabling the assessment of metabolic adaptation. In this study, participants having provided their consent to be re-contacted will be invited to attend the research center 12,18 and 24 months after completing the lifestyle intervention. Body weight and composition will be measured, aiming to explore the association between metabolic adaptation and changes in body weight and composition after a weight loss intervention. In addition, we will explore whether weight and fat mass changes are different between groups, and whether these effects are mediated by metabolic adaptation.

Official Title
-----------------
Role Of Metabolic Adaptation In Weight Regain: Expend Follow-Up

Conditions
-----------------
Weight Loss, Weight Gain, Obesity

Intervention / Treatment
-----------------
* Behavioral: Intensive lifestyle change therapy
* Drug: Tirzepatide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having participated in the study NCT04081337. Exclusion Criteria: Being pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo<br> | Behavioral: Intensive lifestyle change therapy<br>* Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up<br>|
| Tirzepatide<br> | Drug: Tirzepatide<br>* Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight |  | 12 months | 
| Body weight |  | 18 months | 
| Body fat mass (DXA) |  | 12 months | 
| Body fat mass (DXA) |  | 18 months | 
| Body fat mass (DXA) |  | 24 months | 
| Body fat free mass (DXA) |  | 12 months | 
| Body fat free mass (DXA) |  | 18 months | 
| Body fat free mass (DXA) |  | 24 months |
Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back

Detailed Description
-----------------
One of the hidden hormonal imbalance is Toxoplasma infection.Toxoplasmosis is a zoonotic infection the definite host is feline whereas human and other warm blooded animals are intermediate host . Endocrine alterations occuring during toxoplasmosis can be a hidden cause of acne vulgaris

Official Title
-----------------
Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris

Conditions
-----------------
Acne Vulgaris, Toxoplasmosis

Intervention / Treatment
-----------------
* Diagnostic Test: Free testosterone levels and toxoplasma igG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Female patients with active acne vulgaris Exclusion Criteria: Patients with history of hormonal treatment Patients received anti toxoplasma therapy Patients with dermatological diseases caused by hormonal disturbances Pregnant and lactating patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Toxoplasmosis seropositive female patients with active acne vulgaris<br> | Diagnostic Test: Free testosterone levels and toxoplasma igG<br>* Free testosterone levels and toxoplasma igG in serum by ELISA<br>|
| Experimental: Toxoplasmosis seronegative in female patients with active acne vulgaris<br> | Diagnostic Test: Free testosterone levels and toxoplasma igG<br>* Free testosterone levels and toxoplasma igG in serum by ELISA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measuring Toxoplasma igG and free testosterone in acne vulgaris patients and controls | Detect if the toxoplasma latent infection can be associated with disease severity and hormonal disturbances in acne vulgaris female patients | One month |
Predictors of Outcome in Patients With Pleural Infection at Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
pleural infection remains a common medical problem with significant mortality and morbidity despite a better undrstanding of the aetiology , pathophysiology and recent advances in management approaches . the cornerstones of the managment op pleural infection include early identification of cases and accurate diagnosis . suitable antibiotic therapy , nutrition managment , efficient drainage of infected collection via chest tube with or without adjunctive therapies including intrapleural agents and ultimately surgical managment .

Official Title
-----------------
Predictors of Outcome in Patients With Pleural Infection at Sohag University Hospital

Conditions
-----------------
Pleural Infection

Intervention / Treatment
-----------------
* Other: disease outcome ( mortality and length of stay )


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients more than 18 years old with pleural infection Exclusion Criteria: hemothorax chest trauma within 3 month underwent thoracic surgery within 60 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: disease outcome ( mortality and length of stay )|insertion of intercostal tube to drain pleural collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lenght of hospital stay | lenght of hospital stay since admission up to improvement | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality rate | mortality rate related to pleural infection | up to 30 days , 3 months |
Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
It is uncertain whether vitD3 supplementation is beneficial for the remission of Crohn's disease (CD). The effects of vitD3 supplements on the efficacy of ustekinumab in Chinese CD patients were retrospectively analyzed. Methods: Patients with moderate to severe CD were recorded. These patients were initially treated with UST. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of UST and continued throughout the follow-up period. Disease activity was assessed using Harvey Bradshaw Index.

Official Title
-----------------
Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease

Conditions
-----------------
Ustekinumab, Vitamin D Supplementation, Crohn's Disease, Clinical Efficacy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate-to-severe CD Treated with Ustekinumab Exclusion Criteria: had recent supplementation of vitD3 pregnant had cognitive/developmental disorders that affected their ability to complete the study procedures had medical illness or therapies potentially affecting bone, nutrition or growth status unknown or untested baseline serum 25(OH)D level

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| supplementary group<br>take vitamin D supplementation (400 IU/day) during VDZ treatment | |
| non-supplementary group<br>not take vitamin D supplementation (400 IU/day) during VDZ treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum 25 (OH) D level | Vitamin D deficiency is defined as serum 25 (OH) D level<20 μ g/L | 24 weeks | 
| disease activity | Harvey Bradshaw Index，mild: 0 to 8, moderate: 9 to 16, severe: 17 to 25 | 24weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum 25 (OH) D level | Vitamin D deficiency is defined as serum 25 (OH) D level<20 μ g/L | 8 weeks |